Clearside Biomedical Inc (NASDAQ:CLSD) Director Clay Thorp bought 8,000 shares of Clearside Biomedical stock in a transaction on Thursday, December 6th. The stock was acquired at an average price of $1.36 per share, for a total transaction of $10,880.00. Following the transaction, the director now directly owns 8,000 shares of the company’s stock, valued at $10,880. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

CLSD stock opened at $1.37 on Friday. The company has a current ratio of 4.59, a quick ratio of 4.59 and a debt-to-equity ratio of 0.22. Clearside Biomedical Inc has a 12-month low of $1.31 and a 12-month high of $15.33.

Clearside Biomedical (NASDAQ:CLSD) last posted its quarterly earnings data on Thursday, November 8th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.63) by ($0.12). On average, equities research analysts predict that Clearside Biomedical Inc will post -2.57 earnings per share for the current year.

CLSD has been the topic of a number of research analyst reports. ValuEngine upgraded Clearside Biomedical from a “hold” rating to a “buy” rating in a research report on Tuesday, November 6th. Needham & Company LLC set a $4.00 target price on Clearside Biomedical and gave the company a “buy” rating in a research report on Tuesday, November 6th. Laidlaw set a $5.00 target price on Clearside Biomedical and gave the company a “buy” rating in a research report on Tuesday, November 6th. JPMorgan Chase & Co. downgraded Clearside Biomedical from an “overweight” rating to an “underweight” rating in a research report on Monday, November 5th. Finally, Janney Montgomery Scott set a $4.00 target price on Clearside Biomedical and gave the company a “buy” rating in a research report on Tuesday, November 6th. Three analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company’s stock. Clearside Biomedical presently has an average rating of “Hold” and a consensus price target of $12.71.

Several hedge funds have recently bought and sold shares of CLSD. Voya Investment Management LLC purchased a new stake in shares of Clearside Biomedical in the 2nd quarter valued at $123,000. Bank of America Corp DE raised its holdings in shares of Clearside Biomedical by 915.6% in the 2nd quarter. Bank of America Corp DE now owns 16,574 shares of the company’s stock valued at $177,000 after buying an additional 14,942 shares during the period. Trexquant Investment LP purchased a new stake in shares of Clearside Biomedical in the 3rd quarter valued at $188,000. Engineers Gate Manager LP purchased a new stake in shares of Clearside Biomedical in the 3rd quarter valued at $202,000. Finally, Renaissance Technologies LLC purchased a new stake in shares of Clearside Biomedical in the 3rd quarter valued at $216,000. Hedge funds and other institutional investors own 57.94% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Clay Thorp Acquires 8,000 Shares of Clearside Biomedical Inc (CLSD) Stock” was first posted by Daily Political and is the property of of Daily Political. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.dailypolitical.com/2018/12/08/clay-thorp-acquires-8000-shares-of-clearside-biomedical-inc-clsd-stock.html.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema.

Further Reading: Return on Equity (ROE)

Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.